1. Home
  2. SUPN vs PCH Comparison

SUPN vs PCH Comparison

Compare SUPN & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$49.87

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Logo PotlatchDeltic Corporation

PCH

PotlatchDeltic Corporation

HOLD

Current Price

$44.89

Market Cap

3.0B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPN
PCH
Founded
2005
1903
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.0B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
SUPN
PCH
Price
$49.87
$44.89
Analyst Decision
Strong Buy
Hold
Analyst Count
5
6
Target Price
$61.60
$45.83
AVG Volume (30 Days)
632.9K
596.2K
Earning Date
02-24-2026
01-27-2026
Dividend Yield
N/A
3.97%
EPS Growth
N/A
312.61
EPS
N/A
0.82
Revenue
$681,539,000.00
$1,115,571,000.00
Revenue This Year
$8.32
$3.57
Revenue Next Year
$23.64
$0.64
P/E Ratio
N/A
$55.38
Revenue Growth
4.54
5.40
52 Week Low
$29.16
$36.82
52 Week High
$57.65
$48.12

Technical Indicators

Market Signals
Indicator
SUPN
PCH
Relative Strength Index (RSI) 48.53 68.49
Support Level $49.41 $42.23
Resistance Level $52.34 $45.61
Average True Range (ATR) 1.62 1.16
MACD -0.21 0.49
Stochastic Oscillator 38.94 87.89

Price Performance

Historical Comparison
SUPN
PCH

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About PCH PotlatchDeltic Corporation

PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.

Share on Social Networks: